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Abstract
Background: Styrylpyrone derivative (SPD) is a plant-derived pharmacologically active compound
extracted from Goniothalamus sp. Previously, we have reported that SPD inhibited the proliferation
of MCF-7 human breast cancer cells by inducing apoptotic cell death, while having minimal effects
on non-malignant cells. Here, we attempt to further elucidate the mode of action of SPD.
Results: We found that the intrinsic apoptotic pathway was invoked, with the accumulation of
cytosolic cytochrome c and processing of the initiator caspase-9. Cleaved products of procaspase-
8 were not detected. Next, the executioner caspase-7 was cleaved and activated in response to
SPD treatment. To confirm that apoptosis was induced following caspase-7 activation, the caspase
inhibitor Ac-DEVD-CHO was used. Pre-incubation of cells with this inhibitor reversed apoptosis
levels and caspase-7 activity in SPD-treated cells to untreated levels.
Conclusions: Taken together, these results suggest SPD as a potent antiproliferative agent on
MCF-7 cells by inducing apoptosis in a caspase-7-dependent manner.
Background
Cancer is an aberrant net accumulation of atypical cells,
which can arise from an excess of proliferation, an insuffi-
ciency of apoptosis, or a combination of the two [1]. The
frequency of apoptosis could contribute to cell loss in
tumours and promote tumour regression. Thus, in cancer
therapy, the focus is on strategies that suppress tumour
growth by activating the apoptotic program in the cell [2].
Evidence accumulated to this date has established that
many agents of cancer chemotherapy affect tumour cell
killing through launching the mechanisms of apoptosis
[3]. Manifestations of apoptosis are easily discernible by
the appearance of cell shrinkage, membrane blebbing,
chromatin condensation, DNA cleavage, and finally, frag-
mentation of the cell into membrane-bound apoptotic
bodies [4].
Expressed as inactive proenzymes, caspases are members
of a family of cysteine proteases that play a central role in
the apoptotic pathway [5]. Two major mechanisms exist
that initiate the caspase cascade: the extrinsic, involving
caspase-8; and the intrinsic pathway, involving caspase-9
as the apical caspase. Observations from several studies
have suggested that a caspase-8 pathway can be up-regu-
lated after drug treatment, and these include the drugs cis-
platin [6], etoposide [7], doxorubicin and methothrexate
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[8]. Once activated, caspase-8 is thought to activate the
downstream caspases by proteolytic cleavage of their
zymogen forms [9,10], thus amplifying the caspase signal.
The other initiator caspase, caspase-9, controls the apop-
totic response to lethal cellular insults such as ionizing
radiation or certain chemotherapeutic drugs [11]. In
many systems, release of cytochrome c from the mito-
chondria to cytosol has been demonstrated to be a crucial
step in the activation of apoptosis [12–14]. Once released
from mitochondria, cytochrome c acts as a co-factor and
interacts with Apaf-1 and procaspase-9, which in turn acti-
vates caspase-9 [15].
The role of active caspase-8 and -9 is to generate the active
forms of downstream executioner caspases, including cas-
pase-3 and -7, by limited proteolysis, and thereby trans-
mit the apoptotic signal to the execution phase. Activation
of these executioner caspases during apoptosis results in
the cleavage of critical cellular substrates, thus disabling
critical homeostatic and repair enzymes as well as key
structural components that culminate in cell death
[16,17].
Styrylpyrone derivative (SPD) is a pharmacologically
active compound extracted from the plant Goniothalamus
sp. of the Annonaceae family [18]. Among the species of
Goniothalamus are G. umbrosus, G. andersonii, G. macrophyl-
lus and G. malayanus. Previous studies on SPD suggest this
bioactive compound as an antiproliferative and selective
cytotoxic agent. In vitro, SPD was found to selectively
inhibit the proliferation of several cancer cell lines with-
out being significantly cytotoxic towards non-malignant
cells [19–21]. On in vivo models, SPD is reported to be
capable of tumoricidal and tumoristatic effects on experi-
mental rats with mammary tumours [22]. Recent work
done to elucidate SPD's mechanism of action found evi-
dence that SPD modulates the gene expression of Bcl-2
and Bax in ovarian carcinoma [20]. In breast cancer cells,
SPD induces an increase of the proapoptotic Bax protein,
culminating in cell death by apoptosis [21].
Apoptotic levels in SPD-treated cells Figure 1
Apoptotic levels in SPD-treated cells. SPD treatment (10-6 M) significantly increased the level of apoptosis in MCF-7 cells 
when compared to untreated controls, as judged by apoptotic morphology by nuclear staining and DNA fragmentation by 
TUNEL assay described in the Experimental Procedures. Increased levels were observed till 72 hours of SPD treatment. 
Results were presented as the means ± SD of 6 independent experiments.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/16
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In this study, we further demonstrate the mechanism of
apoptosis induced by SPD. We show that procaspase-8
was not activated in MCF-7 cells but caspase-9 activation
was detected in response to SPD treatment, with the
release of cytochrome c  into the cytosol. This was fol-
lowed by the activation of the executioner caspase-7. To
further examine the involvement of this executioner cas-
pase, we found that caspase-7 activity decreased and
apoptosis was abrogated when SPD-treated cells were pre-
incubated with the caspase-7 inhibitor, Ac-DEVD-CHO,
suggesting a caspase-7-dependent apoptotic pathway
induced by SPD.
Results
SPD induced apoptotic cell death
DNA condensation and fragmentation characteristic of
apoptotic cells were examined and quantitated by the
TUNEL assay and nuclear fluorochrome Hoechst 33258.
As reported previously [21], SPD induced apoptosis in
MCF-7 cells at 10-6 M in a time-dependent manner (Figure
1).
Procaspase-8 is not processed in SPD-treated cells
During apoptosis, initiator caspases are activated in
response to proapoptotic signals [23]. By SDS-PAGE and
subsequent Western blot analysis with a caspase-8 specific
antibody, it was found that SPD treatment did not lead to
the activation of the initiator caspase-8. Procaspase-8,
expressed in two functionally active isoforms, caspase-8a
and caspase-8b [24] was not processed. From immunob-
lotting, the two bands observed were the 55/50-kDa pro-
caspase-8 isoforms (Figure 2), similarly reported by Sun et
al., [25] and Dirsch et al., [26] and the active p18 subunit
could not be detected. As processing of this caspase did
not occur, it is possible that the other initiator caspase,
caspase-9 may be involved in SPD-induced apoptosis.
Involvement of caspase-9 and cytochrome c
From immunoblot analysis, untreated MCF-7 cells exhib-
ited the ~48-kDa proform of caspase-9. When MCF-7 cells
were treated with 10-6 M SPD, the observed zymogen of
caspase-9 slowly diminished in the course of the
experiment (Figure 2). The disappearance of the procas-
pase-9 band reflects the processing of the zymogen to gen-
erate the active form of caspase-9, as has been interpreted
in previous reports [27,28].
For activation of caspase-9, a multimeric structure termed
the apoptosome is involved, consisting of cytochrome c,
the apoptotic protease activating factor-1 (Apaf-1), and
ATP or dATP [29]. Cytochrome c seems to be a major trig-
ger for the assembly of this complex, and various studies
have found that cytochrome c is released from the mito-
chondria into the cytosol during cell death [29–31]. When
cytochrome  c  levels in the cytosol were examined, we
detected increasing levels in the SPD-treated MCF-7 cells
(Figure 2). Untreated control cells did not exhibit similar
high levels of cytochrome c, indicating that the release of
cytochrome c from the mitochondria into the cytosol was
an effect of SPD treatment.
The "executioner", caspase-7, is activated in SPD-induced 
apoptosis
The role of the initiator caspase-9 is to generate the active
forms of executioner caspase-3 and -7 by limited proteol-
ysis, and thereby transmit the apoptotic signal to the exe-
cution phase. Here, we used the caspase-3-deficient MCF-
7 cell line. As with previous reports [32,33], caspase-3
activity was not detected (data not shown). Immunoblot
analyses of lysates obtained from MCF-7 cells treated with
SPD at 10-6 M found that caspase-7 was cleaved to the 17-
kDa fragment required for its activation (Figure 3). When
the activity of caspase-7 was assayed, SPD-treated cells
showed increase in activity compared to untreated con-
trols (Figure 4). To confirm that the SPD-induced
Western Blot analysis of apoptotic proteins in SPD-treated  cells Figure 2
Western Blot analysis of apoptotic proteins in SPD-
treated cells. Proteins from MCF-7 cells treated with 10-6 
M SPD for the indicated times were resolved on 12% SDS-
PAGE and submitted to Western Blotting with an anti-pro-
caspase-8 antibody. Two bands were observed, correspond-
ing to the uncleaved 55/50-kDa procaspase-8 isoforms. The 
active p18 subunit was not detected. Samples were also 
detected for procaspase-9 with an anti-procaspase-9 anti-
body (Clone B40). The anti-caspase-9 antibodies recognized 
the proenzyme; and the decrease of this band indicated acti-
vation of caspase-9. When proteins from cytosolic fractions 
of MCF-7 cells treated with 10-6 M SPD were resolved on 
15% SDS-PAGE and submitted to immunoblotting with the 
cytochrome c antibody (Clone 7H8.2C12), increasing 
amounts of cytochrome c were detected in the cytosol in a 
time-dependent manner. All blots were then washed and 
reprobed with β-actin to confirm equal loading.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/16
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apoptotic cell death was due to the involvement of cas-
pase-7, cells were also treated with SPD in the presence of
the specific inhibitor of caspase-7, Ac-DEVD-CHO [34].
SPD-treated cells preincubated with the inhibitor exhib-
ited repressed caspase-7 DEVDase activity. Also, preincu-
bation of MCF-7 cells with this inhibitor at 50 µM to 100
µM inhibited apoptosis and brought apoptotic levels
down to the level similar to controls (Figure 5), thus pur-
porting an apoptotic pathway dependent on caspase-7.
Discussion
There is an increasing realization that chemotherapeutic
agents act primarily by inducing cancer cell death through
the mechanisms of apoptosis [35]. However, there are
many cancers that are intrinsically resistant to apoptosis,
making it vital to develop novel drugs for combination
chemotherapy. In the present study, we provide evidence
that a compound of plant-origin, SPD, may be a promis-
ing new anticancer agent for human breast cancers.
Previously, we have shown that MCF-7 cells treated with
SPD displayed elevated levels of apoptosis and a marked
increase in the expression of the proapoptotic Bax protein
[21]. In addition to the loss of viability, Bax expression
produces other typical manifestations leading to apopto-
sis, namely caspase activation [5]. Here, we found that cas-
pase-9 was activated, together with accumulation of
cytochrome  c  in the cytosol. Caspase-9 can activate
downstream executioner caspases including caspase-7,
which is termed caspase-3-like due to its similarity in spe-
cificity with caspase-3. Caspase-3-like activity has been
detected in the apoptosis induced by various chemother-
apeutic drugs [36]. Caspase-3 deficiency in MCF-7 is due
to a deletion mutation in exon 3 of the gene [32,33]. Pre-
vious studies on MCF-7 with exogenously-expressed cas-
pase-3 indicates that caspase-3 plays an important role in
apoptotic pathways [25,32,33,37]. Studies using etopo-
side and doxorubicin, active chemotherapeutic agents and
key adjuvant drugs for breast cancer treatment, concluded
that MCF-7 cells were sensitized to apoptosis only when
these cells were reconstituted with caspase-3 [38]. Chem-
oresistance is often caused by aberrant apoptosis that in
some instances has been related to defects in caspase acti-
vation [39,40]. Given the importance of caspase-3 in
apoptotic execution, it is then postulated that caspase-3
deficiency might significantly contribute to chemothera-
peutic resistance.
In our studies, we observed manifestations of apoptosis in
SPD-treated MCF-7 cells. Previous reports by Hishikawa
and colleagues [41] and Heerdt et al., [42] have also dem-
onstrated similar apoptotic hallmarks in MCF-7 cells
when induced with connective tissue growth factor
(CTGF) and tributyrin, respectively. These suggest that the
mechanism for induction of apoptosis is present and
functional in MCF-7 cells, but is dependent on the exter-
nal stimuli. Caspase-7 is highly related to caspase-3 and
shows the same synthetic substrate specificity in vitro [43]
suggesting that caspase-3 and -7 have possibly overlap-
ping roles in apoptosis [44]. Without caspase-3, SPD-
treated MCF-7 cells may utilize an alternate caspase path-
way to affect cell death [45]. Here, we demonstrated that
caspase-7 was activated in SPD-induced apoptosis. In
MCF-7 cells treated with SPD, the 35-kDa proenzyme was
Cleavage of procaspase-7 after SPD treatment Figure 3
Cleavage of procaspase-7 after SPD treatment. Pro-
teins from MCF-7 cells treated with 10-6 M SPD for the indi-
cated times were resolved on a 15% PAGE and submitted to 
Western Blotting using a monoclonal antibody against cas-
pase-7 (B94-1), which recognizes the pro- (35-kDa) and the 
active (17-kDa) forms of caspase-7. Following SPD treat-
ment, the caspase-7 proenzyme was cleaved, generating the 
catalytically-active 17-kDa fragment.
Activation of caspase-7 after SPD-treatment Figure 4
Activation of caspase-7 after SPD-treatment. The 
activity of caspase-7 was measured with a Colorimetric 
Assay Kit (Chemicon) that recognizes cleavage of the 
sequence DEVD by active caspase-7. Caspase-7 activity 
increased when cells were treated with SPD, indicating the 
catalytic activation of this executioner caspase. When MCF-7 
cells were incubated with the caspase-7 inhibitor, DEVD-
CHO, prior to SPD treatment, caspase-7 DEVDase activity 
diminished.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/16
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Apoptosis inhibited by DEVD-CHO Figure 5
Apoptosis inhibited by DEVD-CHO. When MCF-7 cells were incubated with the caspase-7 inhibitor, DEVD-CHO at (A) 
50 µM and (B) 100 µM, prior to SPD treatment, apoptosis levels decreased to control untreated levels as detected by nuclear 
staining, suggesting the important role played by this executioner caspase in SPD-induced apoptosis. (C) Results were pre-
sented as the means ± SD of 3 independent experiments.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/16
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cleaved into its active 17-kDa subunit. Synthesized as
inactive precursors, caspases must be proteolytically
cleaved to become active enzymes [16]. Overexpression of
full-length caspase-7 in the MCF-7 does not induce apop-
tosis, whereas the activated 17-kDa subunit induces apop-
totic cell death [46].
Activation of executioner caspases, caspase-3 or -7 results
in the cleavage of critical cellular substrates and homeo-
static enzymes, bringing about the manifestations of
apoptosis [16,23]. Experimental inhibition of apoptosis
by peptide caspase inhibitors presents the opportunity to
investigate the importance of this protease family. When
MCF-7 cells were preincubated with the caspase-7 inhibi-
tor Ac-DEVD-CHO before treatment with SPD, apoptosis
levels decreased to a level similar to controls. Cell death
was thus inhibited and treated cells had morphology sim-
ilar to controls, further supporting the involvement of cas-
pase-7 in SPD-induced apoptosis.
Previous reports have found that MCF-7 cells are relatively
insensitive to many chemotherapeutic agents due to the
absence of caspase-3 [38]. Our studies here have shown
that the mechanism for apoptosis is functional in MCF-7
and SPD is able to induce an alternate caspase pathway,
possibly via caspase-7. Tumours accumulate mutations
that increase their resistance to apoptotic inducers; e.g.
abrogation of caspase-3 has been associated with acquired
multidrug resistance [47]. Therefore, finding new thera-
peutic agents that induce tumour cell apoptosis in a man-
ner independent of caspase-3 may have important clinical
implications. By not requiring caspase-3, SPD may evoke
an apoptotic pathway different from clinical oncology
drugs such as doxorubucin and etoposide [38], thus mak-
ing it a promising agent for combination chemotherapy
that merits further study.
Methods
Cell culture
MCF-7 human mammary carcinoma cells were obtained
from the American Type Culture Collection (ATCC) and
maintained in DMEM supplemented with 10% fetal
bovine serum and 2 mM glutamine. Styrylpyrone deriva-
tive (SPD) was isolated from the bark of Goniothalamus
umbrosus as described previously [48].
Apoptotic index and nuclear morphology
Staining with Hoechst 33258 was done as described pre-
viously [41]. Briefly, cells were treated with SPD at 10-6 M
for various incubation times. For inhibitor studies, cells
were incubated with the caspase-7 inhibitor, Ac-DEVD-
CHO (N-Acetyl-Asp-Glu-Val-Asp-al) (Sigma-Aldrich) 1 h
prior to SPD treatment. After treatment periods, floating
and trypsinized adherent cells were collected and washed
with phosphate-buffered saline (PBS). Cells were then
fixed with 4% paraformaldehyde for 30 min. After
washing, cells were incubated in the nuclear fluoro-
chrome Hoechst 33258 (Sigma) at a final concentration
of 30 µg/ml at room temperature for 30 min. Nuclear
morphology was then examined with a Zeiss fluorescent
microscope and apoptotic cells were counted. DNA frag-
mentation characteristic of apoptotic cells was quantified
by Tdt-mediated dUTP nick end labeling (TUNEL) with
the Apoptosis Detection Kit, Fluorescein (Promega)
according to the manufacturer's instructions. To calculate
the percentage of TUNEL-positive cells, four random
microscopic fields at 100× and 400× magnifications were
taken, and calculations were based on at least 6 independ-
ent experiments.
Isolation of cytosolic fractions
Cytosolic extracts were prepared as previously described
[13]. Briefly, treated cells were harvested by centrifugation
and washed with ice-cold phosphate-buffered saline and
resuspended in 5 volumes of extraction buffer containing
250 mM sucrose. Cells were homogenized and the
homogenates were centrifuged twice at 750 × g for 10 min
at 4°C. The supernatant was then centrifuged at 10,000 ×
g for 15 min at 4°C, and the resulting mitochondrial pel-
lets were discarded. The supernatant was then dissolved in
electrophoresis sample buffer and used for Western
blotting.
Protein extraction for caspases
As previously described [49], cells were scraped with a
rubber policeman after incubation in extraction buffer
and put on ice. Cells were then submitted to 3 freeze-thaw
cycles and centrifuged at 10,000 rpm for 20 min at -4°C.
Supernatant was collected and added with 1:1 sample
buffer and boiled at 95°C for 5 min. After protein concen-
tration was determined by standard procedures, protein
aliquots of 20 µg were applied to 12% or 15% SDS-poly-
acrylamide gels for separation.
Western Blotting
After electrophoresis, proteins were blotted onto polivy-
nyl-difluoride membranes (PolyScreen, Nen Life Science).
Membranes were dried, preblocked with 5% non-fat milk
in phosphate-buffered saline and 0.1% Tween-20, then
incubated with a primary antibody for caspase-8, caspase-
9 (Clone B40), caspase-7 (Clone B94-1) or cytochrome c
(Clone 7H8.2C12) (all from Pharmingen), and detected
with horseradish peroxidase-labeled antibodies to rabbit
or mouse IgG. Following exposure on a Kodak BIOMAX x-
ray film, densitometry analysis was done with a GS 670
Imaging Densitometer with the software Molecular Ana-
lyst (Bio Rad). Blots were stripped with Re-Blot Plus
(Chemicon) before reprobing with β-actin antibody to
determine equal loading.Cancer Cell International 2003, 3 http://www.cancerci.com/content/3/1/16
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Caspase-7 activity assay
Caspase-7 activity in the caspase-3-deficient MCF-7 cells
[32,33] was assayed with the Colorimetric Assay Kit
(Chemicon International, USA) that provides a means to
assay the activity of caspases that recognize the sequence
DEVD. The tetrapeptide DEXD is the optimal recognition
motif for caspase-3 and caspase-7 [23]. The assay was
done according to the manufacturer's instructions. Briefly,
MCF-7 cells were treated with SPD at 10-6 M for 24 and 48
h. After the treatment period, cells were counted and then
pelleted at 1,500 rpm for 10 min. Cells were then
resuspended in chilled Cell Lysis Buffer and incubated on
ice before centrifugation at 10,000 × g for 5 min. The
supernatant (cytosolic extract) was then transferred to a
fresh microcentrifuge tube and put on ice. The protein
concentration for each sample set was then assayed using
standard protocols. Assay mixture was prepared in a 96-
well plate and mixed with Assay Buffer, dH2O and the cas-
pase substrate, Ac-DEVD-pNA, and incubated at 37°C for
1.5 h. For inhibitor studies, the sample was pre-incubated
with the caspase-7 inhibitor, Ac-DEVD-CHO, for 10 min
at room temperature before adding the substrate solution.
After incubation, samples were read with a Dynex MRX
microtiter plate reader at 405 nm. Increase in caspase-7
activity was then determined by comparing the OD read-
ing from the SPD-treated samples with the level of the
untreated control.
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